A highly promising approach to treating HPV-drivenhead andneckcanceris on the way,and it could be in the shape of a simple oral medication.
This isaccording tonewbreakthroughresearch led by Griffith University, whichhas conductedtrials showingthat the drug, Alisertib, testedin trialsto treat other cancers such as lung and kidney,can alsosuccessfullydestroy the cancer cellsassociated withhead andneckcancer.
Human Papilloma Virus (HPV) is the main culprit in head, neck and oral cancers. The virus isthought to be the most common sexually transmitted infection (STI) in the world, and most people are infected with HPV at some time in their lives.
The latest trials — which have taken place over the past three years at Griffith’s Gold Coast campus – have shown a particular enzyme inhibitorin the drug,has the ability to prevent proliferation of HPV cancer cells in advanced head and neck cancers.
A 100 per cent success rate
Led byProfessor Nigel McMillan, program director from Griffith’sMenzies Health Institute Queensland, the trials have shown a 100 per cent success rate in the drug eradicating the cancerous tumoursin animals.
“Head and neck cancers can unfortunately be very difficult to treat, just by the very nature of where they are located in and around the throat, tongue and mouth,” says Professor McMillan.
“This part of the body contains some delicate areas such as the vocal chords and areas relating to speech, taste, smell, saliva etc, therefore there can be some significant side effects with the current treatment options.
“Quality of life is a major consideration in this patient group and therefore a simple oral treatment regimen will have massive benefit over other treatments in terms of reducing some quite drastic side effects.”
In Australia, there are over 5000 new cases of head and neck cancer each year. First line treatments include radiation and surgery (increasingly of the robotic type), followed by chemotherapy, however survival rates of around 70 per cent have remained unchanged for the past 35 years.
Half of all head and neck cancers are known to be caused by the HPV virus, with four times as many men (784) as women (250) estimated to have already died from the disease in Australia during 2018.
In the United States, there are now more cases ofhead andneckcancer than there are cervical cancer, a disease which is now set to become much more rare in Australia dueto the introduction a decade ago of the world-leading national (HPV) vaccination program for schoolchildren.
Professor McMillan says the next step in the research is for the drug to be extended to human trialsat the Gold Coastwith patients for whom other treatments have so far proved unsuccessful.
